Articles

Growing steadily downstream

Affymetrix to acquire eBioscience for $330 million in plan to expand beyond discovery-based efforts
Written byJeffrey Bouley
| 5 min read

SANTA CLARA, Calif.—In a move that Affymetrix Inc. ischaracterizing as a very deliberate and carefully orchestrated one, the companyhas announced that it is acquiring eBioscience Inc., a privately held SanDiego-based company with a notable market presence in flow cytometry andimmunoassay reagents for immunology and oncology research and diagnostics.

In characterizing the value of the eBioscience acquisition,Dr. Frank Witney, president and CEO of Affymetrix, expressed to industrywatchers recently that his company's board of directors feels some "urgency" inits desire to get the company on a growth track, but that the acquisition wascarefully considered. He further noted in a recent conference call to investorsand media that "our aim is to return the company to growth and sustainedprofitability. We expect to achieve these goals through a number of ways,including stabilizing our gene expression business, growing our genotypingmarket share, building a market-leading position in cytogenetics and maintainingconsistent growth of our life science reagents business."

Over the past several months, Witney notes, Affymetrix hasconducted a number of meetings and discussions with investors that have coveredmoves such as mergers and acquisitions and buying back stock.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.